Acrux Ltd. | Income Statement

Fiscal year is July-June. All values AUD Thousands.
2014
2015
2016
2017
2018
Sales/Revenue
53,368.00
24,616.00
28,009.00
23,321.00
2,687.00
Cost of Goods Sold (COGS) incl. D&A
-
-
6,062.00
5,973.00
5,388.00
Gross Income
-
-
21,947.00
17,348.00
2,701.00
SG&A Expense
7,350.00
6,569.00
3,038.00
6,220.00
8,330.00
EBIT
44,605.00
16,622.00
18,909.00
11,128.00
11,031.00
Unusual Expense
-
-
-
10,680.00
5,647.00
Non Operating Income/Expense
1,218.00
380.00
1,365.00
1,155.00
118.00
Pretax Income
43,857.00
16,806.00
18,092.00
94.00
16,125.00
Income Tax
15,887.00
5,676.00
5,111.00
149.00
1,943.00
Consolidated Net Income
27,970.00
11,130.00
12,981.00
243.00
14,182.00
Net Income
27,970.00
11,130.00
12,981.00
243.00
14,182.00
Net Income After Extraordinaries
27,970.00
11,130.00
12,981.00
243.00
14,182.00
Net Income Available to Common
27,970.00
11,130.00
12,981.00
243.00
14,182.00
EPS (Basic)
0.17
0.07
0.08
0.00
0.09
Basic Shares Outstanding
166,521.70
166,521.70
166,521.70
166,521.70
166,521.70
EPS (Diluted)
0.17
0.07
0.08
0.00
0.09
Diluted Shares Outstanding
166,521.70
166,521.70
166,521.70
166,521.70
166,521.70
EBITDA
46,018.00
18,047.00
20,401.00
12,688.00
10,413.00
Non-Operating Interest Income
470.00
564.00
548.00
613.00
671.00

About Acrux

View Profile
Address
103-113 Stanley Street
West Melbourne Victoria (VIC) 3003
Australia
Employees -
Website http://www.acrux.com.au
Updated 07/08/2019
Acrux Ltd. operates as a pooled development fund that invests in pharmaceutical businesses. The firm develops and commercializes pharmaceutical products using unique technology to administer drugs through the skin. It operates through the following geographical segments: Australia, Switzerland, United States, and Other.